Q2 EPS Forecast for Acrivon Therapeutics Raised by Analyst

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – HC Wainwright lifted their Q2 2026 earnings per share estimates for shares of Acrivon Therapeutics in a report released on Thursday, May 14th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.50) per share for the quarter, up from their previous estimate of ($0.57). The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($1.96) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($2.09) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($0.67) EPS and FY2030 earnings at $0.13 EPS.

ACRV has been the subject of several other research reports. Weiss Ratings downgraded Acrivon Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Wall Street Zen downgraded Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, March 1st. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Acrivon Therapeutics in a research note on Monday, March 2nd. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $11.67.

Acrivon Therapeutics Stock Performance

ACRV opened at $1.65 on Tuesday. The company has a market cap of $70.62 million, a PE ratio of -0.83 and a beta of 2.01. The stock has a 50-day moving average of $1.70 and a 200-day moving average of $1.93. Acrivon Therapeutics has a 52-week low of $1.05 and a 52-week high of $3.56.

Acrivon Therapeutics (NASDAQ:ACRV) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.49).

Institutional Trading of Acrivon Therapeutics

Hedge funds have recently modified their holdings of the company. Schonfeld Strategic Advisors LLC acquired a new position in shares of Acrivon Therapeutics in the 4th quarter worth approximately $40,000. Vermillion & White Wealth Management Group LLC acquired a new stake in Acrivon Therapeutics during the 4th quarter valued at $44,000. Focus Partners Wealth acquired a new stake in Acrivon Therapeutics during the 3rd quarter valued at $36,000. Quadrature Capital Ltd acquired a new stake in Acrivon Therapeutics during the 4th quarter valued at $50,000. Finally, Invesco Ltd. acquired a new stake in Acrivon Therapeutics during the 1st quarter valued at $72,000. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.